Compare Novavax Inc (NVAX) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Financial Select Sector SPDR Fund — how do they compare? Novavax Inc trades at $12.79 (market cap $1.82B), while Financial Select Sector SPDR Fund trades at $54.75 (market cap $50.06B). The key difference: Financial Select Sector SPDR Fund is far larger — about 27.5× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Financial Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| NVAX | XLF | |
|---|---|---|
Market Cap | $1.82B | $50.06B |
Volume | 6,198,505 | 47,464,120 |
Sector | Health | — |
52-Week High | $12.56 | $58.55 |
52-Week Low | $6.22 | $47.80 |
Typical Hold Time | 59 Days | 104 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
XLF trades at $54.71, up 1.78% with a bearish technical signal from moving averages. The ETF faces sector headwinds as financial stocks lag the S&P 500 by the widest margin since 1990 despite rising bank profits. Recent Fed stress test changes and interest rate hikes create both opportunities and volatility for financial sector holdings.
Financial sector exposure benefits from rising interest rates but faces regulatory uncertainty and market underperformance risks. The divided Congress outlook suggests limited major legislation, maintaining sector-specific policy focus. XLF's concentrated 76-holding portfolio offers large-cap financial exposure with competitive 0.08% expense ratio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
